Clinical Trial

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

Study acronym: HAMABANK
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-03; most recent amendment 2025-07-25.
Trial Details
NCT Number NCT06629363
Lead Sponsor Centre Hospitalier de PAU
Conditions Malignant Hypertension
Enrollment 1,000 participants
Start Date 2025-08-01
Primary Completion 2036-04-01 (estimated)
Study Completion 2036-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-30